NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Software
Agency / Source: Zinc Ahead Ltd | Veeva Systems

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch - Veeva Link provides biotech with valuable market insights about top scientific and clinical leaders - Oncopeptides-us.com / Veeva.com
Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch

 

NewswireTODAY - /newswire/ - Pleasanton, CA, United States, 2021/05/17 - Veeva Link provides biotech with valuable market insights about top scientific and clinical leaders - Oncopeptides-us.com / Veeva.com. NYSE: VEEV

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Veeva Systems today announced a strategic partnership with Oncopeptides to support the launch of the global biotech’s first commercial product. Using Veeva Link for real-time customer intelligence, Oncopeptides recently launched PEPAXTO® (melphalan flufenamide), the first anticancer peptide-drug conjugate approved by the U.S. Food and Drug Administration (FDA) for multiple myeloma.

“Engaging the right healthcare providers (HCPs) is key in determining how fast we can reach patients battling difficult-to-treat hematological diseases,” said Mohamed H. Ladha, general manager of the U.S. business unit at Oncopeptides. “Veeva Link has given our medical and commercial teams the strategic insights they need to accelerate our launch and make meaningful connections from day one and beyond.”

Oncopeptides used Veeva Link to quickly identify top scientific and clinical experts during pre-commercial planning, better engage with them, and uncover key market-level insights. Veeva Link’s in-depth oncology expert profiles inform more value-driven field interactions both in the critical early days of a launch and throughout ongoing commercialization activities. This supports the company’s field force territory planning, key opinion leader (KOL) mapping, target account profiling, and speaker bureau selection.

The biotech also benefits from Veeva’s full suite of Commercial Cloud applications, including solutions for multichannel engagement, commercial content, and customer data. These capabilities deliver data-driven insights and facilitate smarter, compliant HCP interactions across all channels.

“We’re proud to partner with Oncopeptides to help bring this important therapy to the market,” said Kilian Weiss, general manager for Veeva Link at Veeva Systems. “The company’s dynamic field force is taking a digital-first approach to customer engagement helping accelerate commercial success and support long-term, agile relationships even as HCP preferences and access continue to evolve.”

Used by five of the ten largest pharmaceutical companies, Veeva Link speeds market readiness for new life sciences products. It provides fully compliant, real-time profiles on tens of thousands of scientific experts and millions of activities in a single enterprise view. With this strategic visibility, sales, marketing, and medical teams gain deeper market insights, grow relationships, and add value to customer interactions.

For more information on how Oncopeptides used these market-level insights to accelerate its launch, register for the upcoming Veeva Commercial & Medical North America Summit Connect on June 10, 2021. The live one-day virtual event is open to life sciences industry professionals.

About Oncopeptides

Oncopeptides (oncopeptides.se | oncopeptides-us.com) is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases. Oncopeptides has one U.S. FDA approved product, PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen. PEPAXTO is approved for some patients with triple-class refractory multiple myeloma and was evaluated in several clinical studies including the pivotal Phase 2 HORIZON study and is currently being evaluated in the confirmatory Phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden, with a U.S. headquarters in Boston, Massachusetts. In addition to Boston, Oncopeptides has a footprint in San Francisco, California, another U.S. biotech hub. PEPAXTO® is a trademark of Oncopeptides AB (publ).

About Veeva Systems

Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions,“Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2021. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Zinc Ahead Ltd | Veeva Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
Software Warnings - IMPORTANT:
Always be aware/cautious about what you download on your computer/mobile! PURCHASE SOFTWARE related keywords / Banner Ads. Click HERE for details!
.

 
  Your Banner Ad showing on ALL
Software articles,
CATCH Visitors via Your Competitors Announcements!


Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Oncopeptides | Veeva Systems, Inc.
Contact: Deivis Mercado / Meagan Busath - Veeva.com 
925-226-8821 / 925-452-6500 deivis.mercado[.]veeva.com / meagan.busath[.]veeva.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Zinc Ahead Ltd | Veeva Systems securities in any jurisdiction including any other companies listed or named in this release.

Software via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Zinc Ahead Ltd | Veeva Systems / Company Profile


Read Software Most Recent Related Newswires:

SAP Expands 25-Year Partnership with Lockheed Martin
Siemens Expands Simulation Capability for Electrification and Aerospace Design with Simcenter Mechanical Solutions
Frost & Sullivan Awards Nexthink with the 2022 Company of the Year Award for Improving the Digital Employee Experience
Saadia Group Acquires Visibility Across its Portfolio with NetSuite
Nestlé Purina Petcare Takes Category Management Strategy into the Metaverse with Blue Yonder and 3DVR Solutions
Heart Aerospace Selects Siemens Xcelerator for E/E System Design, Optimization and Certification of New Electric Airplane
Erasmus MC Builds Data-driven Hospital of the Future with SAS and Microsoft
Aptean Recognized in Top Tier of Power 500 Software Companies
WANdisco Launches Data Activation Platform 2.0 to Supercharge Massive Data Movement to Any Cloud
Saudi Lime Selects Infor Cloud to Help Drive Digital Transformation Strategy
Siemens & Deloitte Demonstrate Industry 4.0 innovation at The Smart Factory @ Wichita
Big Boy Improves Cost and Efficiency with Oracle Payment and Inventory Management Tech
GA-ASI Selects Siemens Xcelerator for Digital Transformation
Pick n Pay Selects Blue Yonder to Deliver Localized Planning
Quest Software Announces General Availability of SharePlex 11, Enabling Database Replication Across PostgreSQL and Snowflake Environments

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)